Company Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders.
Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome.
The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Oct 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 226 |
| CEO | Dr. David P. Meeker M.D. |
Contact Details
Address: 222 Berkeley Street Boston, Massachusetts United States | |
| Website | https://www.rhythmtx.com |
Stock Details
| Ticker Symbol | RYTM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001649904 |
| CUSIP Number | 76243J105 |
| ISIN Number | US76243J1051 |
| Employer ID | 46-2159271 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David P. Meeker M.D. | Chairman, President & Chief Executive Officer |
| Hunter C. Smith M.B.A. | Chief Financial Officer & Treasurer |
| Christopher German | Corporate Controller, Principal Accounting Officer & Executive Director |
| David Connolly | Head of Investor Relations & Corporate Communications |
| Dr. Alastair Garfield Ph.D. | Chief Scientific Officer |
| Jennifer Lee | Executive Vice President & Head of North America |
| Jim Flaherty | Senior Vice President & General Counsel |
| Joseph Shulman | Chief Technical Officer |
| Sarah Ryan | Vice President of Sales & Marketing |
| Yann Mazabraud | Executive Vice President & Head of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 13, 2024 | 4/A | [Amend] Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 4 | Filing |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |